Precision oncology company Guardant Health Inc (Nasdaq: GH) announced on Wednesday that it has expanded its Guardant360 Liquid cancer testing capabilities with new epigenomic applications designed to improve treatment selection in advanced breast and lung cancers. Powered by its InfinityAI platform, the enhancements combine genomic and epigenomic insights to identify potential treatment options that conventional genomic biomarkers alone may miss.
The five advances include new epigenomic predictors to identify patients who may benefit from selective oestrogen receptor degraders (SERDs) in advanced breast cancer and immune checkpoint inhibitor (ICI) monotherapy in advanced non-small cell lung cancer (NSCLC). The test will also enable blood-based identification of PD-L1-negative patients without requiring tissue samples.
Additional capabilities use methylation analysis to identify 20-45% of ALK fusions and more than 250% additional MTAP deletions missed by genomic liquid testing alone. These insights could help identify patients eligible for targeted treatments and clinical trials, including emerging PRMT5 and MAT2A inhibitor approaches.
The expanded platform also combines tumour microenvironment characterisation with tumour mutational burden and microsatellite instability to assess potential immunotherapy response and inform treatment decisions between ICI monotherapy and chemoimmunotherapy.
Guardant said the developments extend the clinical applications of its oncology testing portfolio, providing a more comprehensive view of tumour biology to support personalised cancer treatment decisions.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology